rs754824764
Variant summary
Our verdict is Uncertain significance. The variant received 2 ACMG points: 2P and 0B. PM2
The NM_006206.6(PDGFRA):c.1475A>C(p.Lys492Thr) variant causes a missense change. The variant allele was found at a frequency of 0.00000186 in 1,613,858 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. K492N) has been classified as Uncertain significance.
Frequency
Consequence
NM_006206.6 missense
Scores
Clinical Significance
Conservation
Publications
- gastrointestinal stromal tumorInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: ClinGen, Labcorp Genetics (formerly Invitae)
- polyps, multiple and recurrent inflammatory fibroid, gastrointestinalInheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Genomics England PanelApp, Ambry Genetics, G2P
- congenital heart diseaseInheritance: AD Classification: LIMITED Submitted by: ClinGen
- isolated cleft palateInheritance: Unknown Classification: LIMITED Submitted by: Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 2 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| PDGFRA | ENST00000257290.10 | c.1475A>C | p.Lys492Thr | missense_variant | Exon 10 of 23 | 1 | NM_006206.6 | ENSP00000257290.5 | ||
| PDGFRA | ENST00000509092.5 | n.1293A>C | non_coding_transcript_exon_variant | Exon 9 of 15 | 1 | |||||
| PDGFRA | ENST00000509490.5 | n.1475A>C | non_coding_transcript_exon_variant | Exon 10 of 18 | 1 | ENSP00000424218.1 | ||||
| ENSG00000282278 | ENST00000507166.5 | c.1018-1278A>C | intron_variant | Intron 12 of 23 | 2 | ENSP00000423325.1 |
Frequencies
GnomAD3 genomes AF: 0.00000658 AC: 1AN: 152006Hom.: 0 Cov.: 31 show subpopulations
GnomAD2 exomes AF: 0.00000796 AC: 2AN: 251100 AF XY: 0.0000147 show subpopulations
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461852Hom.: 0 Cov.: 33 AF XY: 0.00000275 AC XY: 2AN XY: 727232 show subpopulations
GnomAD4 genome AF: 0.00000658 AC: 1AN: 152006Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 74234 show subpopulations
ClinVar
Submissions by phenotype
Idiopathic hypereosinophilic syndrome;C5193005:Polyps, multiple and recurrent inflammatory fibroid, gastrointestinal Uncertain:1
- -
Polyps, multiple and recurrent inflammatory fibroid, gastrointestinal Uncertain:1
- -
Gastrointestinal stromal tumor Uncertain:1
This sequence change replaces lysine, which is basic and polar, with threonine, which is neutral and polar, at codon 492 of the PDGFRA protein (p.Lys492Thr). This variant is present in population databases (rs754824764, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with PDGFRA-related conditions. ClinVar contains an entry for this variant (Variation ID: 407416). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt PDGFRA protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Hereditary cancer-predisposing syndrome Uncertain:1
The p.K492T variant (also known as c.1475A>C), located in coding exon 9 of the PDGFRA gene, results from an A to C substitution at nucleotide position 1475. The lysine at codon 492 is replaced by threonine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at